Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
recently got another one on January; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix in 2018). On 20-JAN-2025, the patient received the 2nd dose of Shingrix. On 20-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: recently got another one on January). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 25-MAR-2025 The pharmacist's mother received a first dose on 2018 and recently got another one on 20 January 2025, which led to drug dose administration interval too long. Pharmacist wanted to ask if efficacy was affected once there had been more than six months after the first dose.; Sender's Comments: US-GSK-US2025035954:same reporter